DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

The company’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $32.00. Thomas Shrader’s rating is based on Denali ...

Hundreds of truckloads of food, fuel and other supplies have arrived in Gaza each day since the cease-fire took effect. But the need is vast after 15 months of war. By Vivian Yee and Bilal ...

The Walt Disney Company operates as an entertainment company worldwide. It operates through three segments: Entertainment, Sports, and Experiences. The company produces and distributes film and ...

Jan. 24, 2025 — We're nearly one month into 2025, but if you're struggling to hold onto your New Year's resolution, stay strong, as new research shows that forming a healthy habit can take ...

Security Information and Event Management (SIEM) systems are now a critical component of enterprise security. Learn more from Smarttech247 about how its VisionX + Splunk solution can help secure ...